Sorry, you need to enable JavaScript to visit this website.

All announcements

Announcement Date

Exact Sciences and Pfizer Enter into a U.S. Agreement for Cologuard®

On August 22, 2018, Exact Sciences Corp. and Pfizer Inc. announced an agreement to co-promote Cologuard, the FDA-approved non-invasive stool DNA screening test for colorectal cancer. Pfizer joins Exact Sciences' colleagues in reaching both physicians and health systems and also actively participates in extending and deepening the Cologuard development. For further medical information, please call Exact Sciences Provider Support Line 1-844-870-8870
October 8, 2018

U.S. FDA Approves VIZIMPRO® (dacomitinib) for the First-Line Treatment of Patients with EGFR-Mutated Metastatic NSCLC

On September 27, 2018, the U.S. FDA approved VIZIMPRO® [vih-ZIM-pro] (dacomitinib), a kinase inhibitor for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test. The safety and efficacy of VIZIMPRO was demonstrated in the randomized, open-label, phase 3 study, ARCHER 1050 (NCT01774721). Please see the full press release via the link below for further details.
September 28, 2018

Nivestym FDA Approval

U.S. FDA Approves Pfizer’s Biosimilar NIVESTYM™ (filgrastim-aafi)
July 24, 2018

Hospira Issues Voluntary Nationwide Recall of Daptomycin for Injection Lyophilized Powder for Solution, due to Infusion Reactions

June 29, 2018

FDA approves Xeljanz for moderately to severely active ulcerative colitis

May 30, 2018

Observational Data Shows Real-World Effectiveness of Prevnar® 13 in Adults Age 65+

May 24, 2018

Pfizer’s Biosimilar RETACRIT® (epoetin alfa-epbx) Approved by U.S. FDA

On 5/15/2018, Pfizer Inc. announced the United States (U.S.) Food and Drug Administration (FDA) approved RETACRIT® (epoetin alfa-epbx), a biosimilar to Epogen® and Procrit® (epoetin alfa), for all indications of the reference product. Please see the full press release via the link below for further details.
May 15, 2018

Overview of Quillivant XR (video presentation)

February 22, 2017